Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Doxylamine/pyridoxine controlled-release - Duchesnay

Next Previous
Drug Profile

Doxylamine/pyridoxine controlled-release - Duchesnay

Alternative Names: Bonjesta; Diclectin; Diclegis; Doxylamine succinate/pyridoxine hydrochloride; Pyridoxine/doxylamine; Xonvea

Latest Information Update: 23 Apr 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Duchesnay Inc
  • Developer Duchesnay Inc; Tzamal Medical
  • Class Alcohols; Amines; Antiemetics; Benzene derivatives; Ethers; Picolines; Pyridines; Small molecules; Vitamins
  • Mechanism of Action Biogenic monoamine uptake modulators; Histamine H1 receptor antagonists; Neurotransmitter stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Morning sickness
  • Phase III Hyperemesis gravidarum

Most Recent Events

  • 30 Mar 2026 Duchesnay suspended phase III trials in Morning sickness (In adolescents) in USA (PO), due to the number of patients being so small, rendering the study unfeasible within a reasonable period of time (NCT05289557)
  • 03 Feb 2026 Doxylamine/pyridoxine controlled-release is still in phase III trials in Morning sickness (In adolescents) in USA (PO) (NCT05289557)
  • 21 Mar 2022 Duchesnay plans a phase III trial for Morning sickness (In children, In adolescents) in USA (PO, Tablet) (NCT05289557)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top